PCM
EPZM

Prelude Capital Management’s Epizyme, Inc EPZM Stock Holding History

Prelude Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,812
Closed -$334K – 2528
2020
Q2 		$334K Buy
20,812
+2,179
+12% +$38K 0.02% 592
2020
Q1 		$289K Buy
18,633
+3,630
+24% +$78K 0.02% 389
2019
Q4 		$369K Buy
15,003
+14,301
+2,037% +$212K 0.01% 653
2019
Q3 		$7K Sell
702
-71,998
-99% -$908K ﹤0.01% 1537
2019
Q2 		$912K Buy
72,700
+71,755
+7,593% +$923K 0.04% 366
2019
Q1 		$12K Sell
945
-253
-21% -$2.83K ﹤0.01% 1413
2018
Q4 		$7K Buy
1,198
+642
+115% +$4.9K ﹤0.01% 1496
2018
Q3 		$6K Buy
+556
New +$6.35K ﹤0.01% 1622
2017
Q2 		– Sell
-23,243
Closed -$399K – 1944
2017
Q1 		$399K Sell
23,243
-4,979
-18% -$66.3K 0.04% 368
2016
Q4 		$341K Buy
+28,222
New +$295K 0.04% 401
2015
Q2 		– Sell
-2,400
Closed -$45K – 2148
2015
Q1 		$45K Sell
2,400
-5,400
-69% -$112K 0.01% 1352
2014
Q4 		$147K Buy
7,800
+2,300
+42% +$53.7K 0.02% 839
2014
Q3 		$149K Buy
5,500
+4,200
+323% +$131K 0.02% 845
2014
Q2 		$40K Sell
1,300
-1,600
-55% -$37.7K 0.01% 1477
2014
Q1 		$66K Buy
+2,900
New +$87.9K 0.01% 1188

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Prelude Capital Management's EPZM Position: Q3 2020 in Review

Prelude Capital Management sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 20,812 shares — an estimated $334K sold.

Prelude Capital Management first reported a position in EPZM in Q1 2014 and held it in 15 quarters. The position peaked at $912K in Q2 2019. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Prelude Capital Management reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 20,812 Epizyme, Inc shares in Q3 2020, an estimated $334K.
  • Prelude Capital Management first reported a position in Epizyme, Inc in Q1 2014 and held it in 15 quarters.
  • Prelude Capital Management's Epizyme, Inc position peaked at $912K in Q2 2019.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.